Medindia

X

IPC The Hospitalist Company Reports Second Quarter 2010 Results

Tuesday, July 27, 2010 Hospital News J E 4
Advertisement
NORTH HOLLYWOOD, Calif., July 26 IPC The Hospitalist Company, Inc. (Nasdaq: IPCM), a leading national hospitalist physician group practice, today announced financial results for the second quarter ended June 30, 2010.

Second Quarter 2010 Highlights (comparisons are to second quarter 2009):

Six Months Ended June 30, 2010 Highlights (comparisons are to six months ended June 30, 2009):

Adam D. Singer, M.D., Chief Executive Officer of IPC The Hospitalist Company, stated, "Our second quarter results, including a 17% increase in net revenue, clearly demonstrated our continued ability to grow our top-line from both existing markets and new market acquisitions. As we grew our top-line, we were able to reduce our practice costs as a percentage of revenue, which contributed to an 80 basis point improvement in our operating margin for the quarter and year to date periods."

Dr. Singer added, "We continue to execute on our strategy through a combination of organic and acquisition growth. We completed five acquisitions year to date this year, two of which represent our continued expansion into sub-acute care. Our acquisition pipeline is robust, as the industry remains highly fragmented. We are confident that we will continue to execute our dual-pronged growth strategy for the remainder of 2010 and beyond."

Second Quarter 2010

Patient encounters for the three months ended June 30, 2010 increased 15.6% to 920,000, compared to 796,000 for the same period last year. Net revenue for the three months ended June 30, 2010 was $87.6 million, an increase of $12.8 million, or 17.2%, from $74.8 million for the three months ended June 30, 2009. Of this $12.8 million increase, $8.7 million or 68.0% was attributable to same-market area growth and $4.1 million, or 32.0%, was attributable to revenue generated from two new markets which were entered through acquisitions in 2009. Same-market encounters increased 11.0% and patient revenue per encounter increased 1.6% resulting in an increase in same-market patient revenue of 12.8%. Same-market hospital contract and other revenue decreased slightly resulting in an overall 11.6% increase in same market net revenue.

Physician practice salaries, benefits and other expenses for the three months ended June 30, 2010 were $63.1 million, or 71.9% of net revenue, compared to $54.5 million, or 72.9% of net revenue, for the three months ended June 30, 2009.

General and administrative expenses increased $2.3 million, or 18.0%, to $15.0 million, or 17.1% of net revenue, for the three months ended June 30, 2010, as compared to $12.7 million, or 17.0% of net revenue, for the three months ended June 30, 2009.

Income from operations increased $1.9 million, or 27.1%, to $8.9 million, as compared to $7.0 million for the same period in the prior year. The operating margin increased to 10.2% for the three months ended June 30, 2010, up 80 basis points from an operating margin of 9.4% for the three months ended June 30, 2009.

The effective tax rate for the three months ended June 30, 2010 was 39.0% compared to 40.0% for the three months ended June 30, 2009. The decrease in the effective tax rate reflects a change in our effective state tax rate.

Net income increased to $5.4 million for the three months ended June 30, 2010, as compared to $4.1 million for the three months ended June 30, 2009 and net income margin increased to 6.2% from 5.5% for the same period in the prior year. Earnings per diluted share for the second quarter of 2010 were $0.33, compared to earnings per diluted share of $0.25 for the second quarter of 2009, an increase of 32.0%.

Six Months Ended June 30, 2010

Patient encounters for the six months ended June 30, 2010 increased 15.0% to 1,847,000, compared to 1,606,000 for the same period last year. Net revenue for the six months ended June 30, 2010 was $175.3 million, an increase of $24.5 million, or 16.2%, from $150.8 million for the six months ended June 30, 2009. Of this $24.5 million increase, $16.5 million or 67.3% was attributable to same-market area growth and $8.0 million, or 32.7% was attributable to revenue generated from two new markets which were entered through acquisitions in 2009. Same-market encounters increased 10.5% and patient revenue per encounter increased 1.6% resulting in an increase in same-market patient revenue of 12.2%. Same-market hospital contract and other revenue decreased slightly resulting in an overall 10.9% increase in same-market net revenue.

Physician practice salaries, benefits and other expenses for the six months ended June 30, 2010 were $126.7 million, or 72.3% of net revenue, compared to $109.9 million, or 72.9% of net revenue, for the six months ended June 30, 2009.

General and administrative expenses increased $3.9 million, or 15.3%, to $29.0 million, or 16.5% of net revenue, for the six months ended June 30, 2010, as compared to $25.1 million, or 16.7% of net revenue, for the six months ended June 30, 2009.

Income from operations increased $3.7 million, or 25.8%, to $18.3 million, as compared to $14.6 million for the same period in the prior year. The operating margin increased to 10.5% for the six months ended June 30, 2010, up 80 basis points from an operating margin of 9.7% for the six months ended June 30, 2009.

The effective tax rate for the six months ended June 30, 2010 was 39.0% compared to 40.0% for the six months ended June 30, 2009. The decrease in the effective tax rate reflects a change in our effective state tax rate.

Net income increased to $11.2 million for the six months ended June 30, 2010, as compared to $8.6 million for the six months ended June 30, 2009 and net income margin increased to 6.4% from 5.7% for the same period in the prior year. Earnings per diluted share for the six month period ended June 30, 2010 were $0.67, compared to earnings per diluted share of $0.53 for the same period last year, an increase of 26.4%.

Liquidity and Capital Resources

As of June 30, 2010 we had approximately $64.5 million in liquidity, comprised of $34.6 million in cash and cash equivalents, no debt outstanding and an available line of credit of $29.9 million.

Net cash provided by operating activities for the six months ended June 30, 2010 was $15.1 million, compared to $17.3 million for the same period of 2009. The reduction in net cash provided by operations was the result of an increase in accounts receivable and a decrease in accrued compensation. The increase in accounts receivable was due to higher revenue and to the fact that Medicare reimbursement was delayed during the month of June 2010, by order of the Centers for Medicare and Medicaid Services (CMS) prior to Congressional action to increase Medicare rates. Claims are no longer being held by CMS. The decrease in accrued compensation was the result of fewer days of unpaid payrolls as of June 30, 2010. Although accounts receivable increased since December 31, 2009, our days sales outstanding (DSO) decreased to 53.5 DSO as of June 30, 2010, compared to 54.1 DSO as of December 31, 2009. During the first six months of 2010, $12.2 million was used for the acquisition of four physician practices and for earn-out payments on prior acquisitions, compared to $7.9 million in the same period of the prior year.

2010 Guidance

The Company reaffirms its guidance for the full year 2010 and expects revenue to be in the range of $352 million to $361 million and earnings per diluted share to be in the range of $1.34 to $1.43. The Company has provided this outlook based on the following assumptions: (i) weighted average shares outstanding of 16.6 million for the year; (ii) a 39.0% effective tax rate, and (iii) Congress passing legislation to prevent the scheduled December 1, 2010 reduction in the Medicare Physician Fee Schedule. Not included in the assumptions are (i) practice acquisitions completed after today's date, or (ii) gains or losses related to changes in estimates of earn-outs attributable to practice acquisitions that closed subsequent to December 31, 2008.

Conference Call Information

IPC The Hospitalist Company (IPC) will host an investor conference call to review the quarterly results at 5:00 p.m. ET (2:00 p.m. PT) today. To participate in the conference call, please dial 877-225-7695 (USA) or 720-545-0027 (International). In addition, a dial-up replay of the conference call will be available beginning July 26, 2010 at 8:00 p.m. ET (5:00 p.m. PT) and ending on August 9, 2010 at 11:59 p.m. The replay telephone number is 800-642-1687 (USA) or 706-645-9291 (International). Please use the conference ID number 87262946 to access the reply. A live webcast of the call will also be available from the Investor Relations section on the corporate web site at www.hospitalist.com. A webcast replay can be accessed on the corporate web site beginning July 26, 2010 at approximately 8:00 p.m. ET (5:00 p.m. PT) and will remain available until August 26, 2010 at 11:59 p.m.

About IPC The Hospitalist Company

IPC The Hospitalist Company, Inc. (Nasdaq: IPCM) is a leading physician group practice company focused on the delivery of hospitalist medicine and related facility-based services. IPC's physicians and affiliated providers manage the care of patients in coordination with primary care physicians and specialists. The Company offers its providers the comprehensive training, information technology, and management support systems necessary to improve the quality and reduce the cost of patient care in the facilities it serves. For more information, visit the IPC website at www.hospitalist.com.

Safe Harbor Statement

Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release may include, but are not limited to, those statements set forth under the section titled "Guidance" regarding projected revenues and earnings, and statements regarding IPC's growth opportunities and strategy. Forward-looking statements are often characterized by terminology such as "believe", "hope", "may", "anticipate", "should", "intend", "plan", "will", "expect", "estimate", "project", "positioned", "strategy" and similar expressions. Any forward-looking statements are necessarily based on a variety of estimates and assumptions which, though considered reasonable by the Company, may not be realized and are inherently subject to significant business, economic, competitive, industry, regulatory, market and financial uncertainties and contingencies, many of which are and will be beyond IPC's control. Important risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by any forward-looking statements are described in IPC's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 22, 2010, including the section titled "Risk Factors", and actual results could differ materially from those anticipated in forward-looking statements.

In particular the following risks and uncertainties may have such an impact:

IPC undertakes no obligation following the date of this press release to update or revise any such statements or projections whether as a result of new information, future events, or otherwise.





-- Net revenue increased 17% to $87.6 million, with same-market area net revenue growth of 12% -- Patient encounters increased 16% to 920,000 -- Income from operations rose 27% to $8.9 million -- Operating margin improved 80 basis points to 10.2% -- Net income increased 32% to $5.4 million, or $0.33 per diluted share

SOURCE IPC The Hospitalist Company, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Popularity of Cosmetic Surgery Growing Among Minor...
S
FDA Clears Prodesse's ProFAST(TM)+ Assay to Identi...